Journal
BIODRUGS
Volume 24, Issue 4, Pages 225-235Publisher
ADIS INT LTD
DOI: 10.2165/11536140-000000000-00000
Keywords
-
Categories
Funding
- NIH [1R01AI075315]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI075315] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Unmethylated cytosine-phosphate-guanine (CpG) dinucleotides in microbial DNA sequences activate Toll-like receptor (TLR) 9, and previous studies have shown that oligodeoxynucleotides (ODNs) containing CpG in specific base sequence motifs (CpG ODNs) can reiterate the majority of the immunomodulatory effects produced by bacterial DNA. Many of the manifestations in allergic diseases are primarily due to T helper (T-h)-2 cell-type responses. CpG ODNs can induce T(h)1 and T-regulatory (T-reg) cell-type cytokines that can suppress the T(h)2 response. The therapeutic application of TLR9 has been explored extensively in recent years, and many studies are being conducted to assess the safety and efficacy of TLR9 agonists in various diseases, including atopic and infectious diseases, and cancer. Studies in murine models have shown that the development of atopic airway disease can be prevented by treatment with CpG ODNs. Various clinical trials are currently ongoing to determine the efficacy of CpG ODNs as a therapeutic tool for atopic diseases. In this review, we discuss the therapeutic application of CpG ODNs in allergy and asthma. CpG ODNs may be used alone or as an adjuvant to immunotherapy to treat these disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available